الفهرس 
Novel oral anticoagulant medicationsOnly 14 pages are availabe for public view
 |  | from | 301 |  |  |
| | | from | 301 | | |
Abstract
Long-term prophylaxis with oral anticoagulants (OACs) is now widely recommended by international guidelines to prevent stroke in all atrial fibrillation (AF) patients without contraindications presenting an independent risk factor for stroke. However, there are several important considerations in the management of patients taking OACs, starting with initiation of therapy.[1] The initial phase of anticoagulant therapy, especially in patients with newly diagnosed AF, is of concern: early bleeding and thromboembolic risks have been observed to be significantly higher during the first 60 days of therapy in AF patients initiating warfarin.[.